Last reviewed · How we verify
Expanded antimicrobial therapy
Expanded antimicrobial therapy uses a broadened spectrum of antimicrobial agents to treat infections caused by multiple pathogenic organisms simultaneously.
Expanded antimicrobial therapy uses a broadened spectrum of antimicrobial agents to treat infections caused by multiple pathogenic organisms simultaneously. Used for Polymicrobial infections, Empiric treatment of severe infections with uncertain etiology.
At a glance
| Generic name | Expanded antimicrobial therapy |
|---|---|
| Sponsor | University of Virginia |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This approach involves the concurrent or sequential use of multiple antimicrobial drugs with different mechanisms of action and spectrum coverage to address polymicrobial infections or infections with uncertain etiology. The strategy aims to improve clinical outcomes by ensuring adequate coverage of likely pathogens while minimizing the development of antimicrobial resistance through combination therapy.
Approved indications
- Polymicrobial infections
- Empiric treatment of severe infections with uncertain etiology
Common side effects
- Drug interactions
- Organ toxicity (hepatic, renal)
- Allergic reactions
- Gastrointestinal disturbances
Key clinical trials
- STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis (PHASE3)
- Antibiotic Strategy and Asymptomatic Bacteriuria in the Context of Intra-vesical Botulinum Toxin A Injections. (NA)
- Expanded Access to Cyclic Irrigation in Patients Undergoing Exchange Arthroplasty
- Extending Dental Care to Nursing Home Residents to Reduce Mouth Infections and Incidence of Pneumonia and Improve Diabetic Glucose Control (NA)
- Cohort of the Specialist Network Infectious Diseases
- Clinical Trial to Assess the Safety and Efficacy of Investigational Product in Patients Due to Hypospadias Treatment Failure (PHASE1, PHASE2)
- Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients (NA)
- Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Expanded antimicrobial therapy CI brief — competitive landscape report
- Expanded antimicrobial therapy updates RSS · CI watch RSS
- University of Virginia portfolio CI